Biogen submits Amevive BLA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen completes U.S. and European marketing applications on Aug. 6 for Amevive (alefacept) for treatment of moderate to severe chronic plaque psoriasis. The BLA filing is receiving a standard review at FDA